Literature DB >> 15515151

More powerful two-sample tests for differences in repeated measures of adverse effects in psychiatric trials when only some patients may be at risk.

Robert P McMahon1, Stephan Arndt, Robert R Conley.   

Abstract

Common adverse effect measures in psychiatric trials are typically analysed with repeated measures ANOVA, despite having distributions which violate key assumptions of that method; moreover, some adverse effects may be concentrated in vulnerable subgroups of participants. For testing treatment differences in adverse effects, we propose use of Kendall's taub as a summary measure of within-participant trends in adverse events, in conjunction with a weighted modification of a rank test proposed by Conover and Salsburg. Data on extrapyramidal side effects from a controlled clinical trial conducted in persons with treatment resistant schizophrenia was used to compare the proposed analysis to repeated measures ANOVA using mixed models and alternate tests for treatment differences in taub trend scores. 2004 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15515151     DOI: 10.1002/sim.1837

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  5 in total

1.  A randomized clinical trial of MK-0777 for the treatment of cognitive impairments in people with schizophrenia.

Authors:  Robert W Buchanan; Richard S E Keefe; Jeffrey A Lieberman; Deanna M Barch; John G Csernansky; Donald C Goff; James M Gold; Michael F Green; L Fredrik Jarskog; Daniel C Javitt; David Kimhy; Michael S Kraus; Joseph P McEvoy; Raquelle I Mesholam-Gately; Larry J Seidman; M Patricia Ball; Robert P McMahon; Robert S Kern; James Robinson; Stephen R Marder
Journal:  Biol Psychiatry       Date:  2010-12-08       Impact factor: 13.382

2.  Adjunctive Minocycline in Clozapine-Treated Schizophrenia Patients With Persistent Symptoms.

Authors:  Deanna L Kelly; Kelli M Sullivan; Joseph P McEvoy; Robert P McMahon; Heidi J Wehring; James M Gold; Fang Liu; Dale Warfel; Gopal Vyas; Charles M Richardson; Bernard A Fischer; William R Keller; Maju Mathew Koola; Stephanie M Feldman; Jessica C Russ; Richard S E Keefe; Jennifer Osing; Leeka Hubzin; Sharon August; Trina M Walker; Robert W Buchanan
Journal:  J Clin Psychopharmacol       Date:  2015-08       Impact factor: 3.153

3.  Adjunctive risperidone for partially responsive people with schizophrenia treated with clozapine.

Authors:  Elaine Weiner; Robert R Conley; M Patricia Ball; Stephanie Feldman; James M Gold; Deanna L Kelly; Ikwunga Wonodi; Robert P McMahon; Robert W Buchanan
Journal:  Neuropsychopharmacology       Date:  2010-07-21       Impact factor: 7.853

4.  Lack of beneficial galantamine effect for smoking behavior: a double-blind randomized trial in people with schizophrenia.

Authors:  Deanna L Kelly; Robert P McMahon; Elaine Weiner; Douglas L Boggs; Dwight Dickinson; Robert R Conley; Robert W Buchanan
Journal:  Schizophr Res       Date:  2008-06-11       Impact factor: 4.939

5.  On summary measure analysis of linear trend repeated measures data: performance comparison with two competing methods.

Authors:  Mehrdad Vossoughi; S M T Ayatollahi; Mina Towhidi; Farzaneh Ketabchi
Journal:  BMC Med Res Methodol       Date:  2012-03-22       Impact factor: 4.615

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.